Resolves as YES if the Phase 3 trials of Olpasiran demonstrate:

Efficacy:

• The trials must show a statistically significant reduction in lipoprotein(a) [Lp(a)] levels in participants compared to baseline, achieving at least a 50% reduction in median Lp(a) levels.
  

• A high percentage of participants achieving Lp(a) levels below 125 nmol/L and 75 nmol/L.
  

• Consistent reduction of Lp(a) levels maintained over the trial period.
  
  

Safety:

• The trials must confirm that Olpasiran is safe for participants, with no significant adverse events that would outweigh the benefits.
  

• Minimal and manageable side effects.
  

• Few serious adverse events linked to the drug's administration.
  
  

Regulatory Progress:

• The trial results must be sufficient to warrant progression towards regulatory approval, as determined by the relevant regulatory bodies or the sponsoring company (Amgen).

Background: Olpasiran is a small interfering RNA (siRNA) therapeutic designed to reduce the production of apolipoprotein(a) in the liver by targeting the mRNA that encodes apolipoprotein(a). Elevated Lp(a) levels are a known risk factor for atherosclerotic cardiovascular disease (ASCVD), and effective reduction of these levels could significantly impact patient outcomes.

The ongoing Phase 3 trial, which began in January 2023, aims to confirm the promising results observed in earlier phases. This trial is crucial for determining the long-term efficacy and safety profile of Olpasiran, with results expected to be published around 2025.